ArticleCureus2025
Measuring Adipocytokines in Young Patients With Type 2 Diabetes Presenting to a Tertiary Care Centre in Upper Assam, India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes mellitus (T2DM) in lean and young adults is emerging as a distinct phenotype in South Asia, often dissociated from obesity-driven insulin resistance. This study evaluated adipocytokines (adiponectin and leptin) and inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)) in young T2DM and non-diabetic individuals across body mass index (BMI) categories to elucidate underlying metabolic and inflammatory profiles. Methods A hospital-based case-control analysis was conducted among 176 individuals (age and sex matched, 83 diabetics, 93 non-diabetics) aged 18-45 years (105 females, 71 males), drawn from the PHENOEINDY-2 cohort at Assam Medical College and Hospital, Dibrugarh. Participants were stratified into four BMI groups: underweight (<18.5 kg/m²), normal (18.5-24.9 kg/m²), overweight (25.0-29.9 kg/m²), and obese (>30 kg/m²). Serum adiponectin, leptin, IL-6, and high-sensitivity CRP (hs-CRP) were measured using enzyme-linked immunosorbent assay (ELISA)-based assays. Statistical comparisons employed t-tests, ANOVA, and regression modeling, adjusting for age and socioeconomic factors. Results Among diabetics, mean adiponectin was highest in the underweight group (3.44 ± 2.56 µg/mL) and declined with increasing BMI, showing a significant negative correlation with BMI (r = -0.65, P = 0.079). Leptin demonstrated a strong positive correlation with BMI (r = 0.77, P = 0.024), increasing progressively from underweight (0.54 ± 0.66 ng/mL) to obese participants (0.80 ± 0.96 ng/mL). CRP levels were markedly elevated in underweight diabetics (8.15 ± 11.9 mg/L) versus non-diabetics (2.19 ± 1.75 mg/L, P = 0.075), suggesting low-grade inflammation even in non-obese individuals. A positive association between CRP and BMI (r = 0.67, P = 0.012) was observed overall. IL-6 levels peaked among normal-weight (102.36 ± 179.5 pg/mL) and overweight diabetics (118.72 ± 163.38 pg/mL), without significant correlation with BMI (r = -0.12, P = 0.777), indicating adiposity-independent inflammation. Logistic regression incorporating all biomarkers yielded a modest predictive accuracy of 33.3%, with CRP emerging as the most influential predictor of diabetes risk, followed by IL-6. Scatter plots confirmed negative trends for adiponectin and positive associations for leptin and CRP with BMI, while IL-6 remained BMI-independent. Interpretation Lean diabetics exhibited distinct biochemical features - higher adiponectin but elevated CRP and IL-6 - supporting inflammation and β-cell dysfunction as key drivers over insulin resistance. In contrast, obese diabetics demonstrated low adiponectin and high leptin, reflecting adiposity-linked metabolic stress. The elevated inflammatory markers among lean diabetics highlight non-adipose origins of inflammation, possibly from hepatic or immune pathways. Conclusions This study underscores heterogeneity in T2DM pathophysiology across BMI categories in Northeast India. Inflammation, rather than adiposity, may underlie dysglycemia among lean individuals, while adipokine imbalance predominates in obesity-associated diabetes. Integrating adiponectin, CRP, and IL-6 into risk assessment could refine screening for atypical or lean T2DM phenotypes. Future longitudinal and genetic studies are warranted to dissect the contribution of developmental and ethnic factors unique to this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.